

**24 November 2025**

ASX Announcement

## **Acceptance into the Medical Countermeasures Coalition to advance US procurement and stockpiling opportunities**

- **Membership granted to the Medical Countermeasures Coalition (MC2) – a key step in advancing Galidesivir as a priority antiviral countermeasure**
- **Coalition includes major biotechnology companies and existing US Strategic National Stockpile suppliers**
- **MC2 is led by former senior US officials and industry experts with experience in countermeasure deployment and government procurement**
- **Inclusion expected to support upcoming regulatory, clinical and stockpiling milestones, as well as US Government engagement initiatives**

**MELBOURNE Australia, 24 November 2025:** Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to advise it has been granted membership into the Medical Countermeasures Coalition (MC2). This marks an important milestone in the progression of the Company's stated strategy to advance Galidesivir as a critical countermeasure against high priority threats and for inclusion in government stockpiles.

MC2 is an international alliance of non-profit organisations, academic groups, and industry partners dedicated to advancing the development, accessibility, and deployment of medical countermeasures. Including vaccines, therapeutics, diagnostics, and related technologies. The group's broader aim is to protect global populations against emerging infectious diseases, pandemics, and biological threats.

The coalition's focus is to strengthen preparedness and response systems by promoting supportive policies, encouraging sustained R&D funding, fostering collaboration across sectors, and ensuring that lifesaving countermeasures can be rapidly deployed when and where they are most needed.

Existing coalition members include a number of major biotechnology companies and current suppliers to the US Government's Strategic National Stockpile, such as SIGA Technologies Inc. (NASDAQ: SIGA), Bavarian Nordic A/S, Ginkgo BioWorks Holdings Inc. (NYSE: DNA), CSL Seqirus (part of ASX: CSL) and Genentech (part of Roche Group SWX: ROG) amongst others. Its Board includes former senior US Government biodefence officials and industry executives with decades of experience in medical countermeasures development and deployment.

Island's inclusion follows the appointment of leading Washington DC-based governmental affairs firm Todd Strategy Group to accelerate US government engagement (refer ASX announcement: 20 November 2025). Coalition membership is expected to assist the Company's ongoing advancement of the Galidesivir program ahead of pending regulatory, clinical and stockpiling opportunities, in pursuit of inclusion in the US Government's Strategic National Stockpile.



**Image:** Membership highlighted on MC2 conference collateral

### **Management Commentary**

**CEO and Managing Director, Dr David Foster said:** *“Membership in the Medical Countermeasures Coalition represents important validation of Island’s strategy to progress Galidesivir as a frontline antiviral countermeasure. MC2 brings together globally recognised experts in biodefence, health-security and medical countermeasure deployment and will assist to strengthen our engagement across the US Government. We are now well positioned to leverage a number of experts across these fields, as well as engage with existing providers to the Strategic National Stockpile top continue to advance the Galidesivir program towards near term regulatory, clinical and stockpiling milestones.”*

**- Ends -**

### **Approved for release to the ASX by:**

David Foster (CEO and Managing Director)  
Island Pharmaceuticals Limited  
[info@islandpharmaceuticals.com](mailto:info@islandpharmaceuticals.com)

Investors and media, for further information, please contact:

Henry Jordan  
Six Degrees Investor Relations  
+61 (0) 431 271 538  
[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)



## **About Island Pharmaceuticals**

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit [www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com) for more on Island.

For personal use only